Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193945 · ClinicalTrials.gov registry record
A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA
A clinical trial, sponsored by ThromboGenics.
- Completed
- Registry status
- 134
- Enrollment target
NCT02193945: Completed study, sponsored by ThromboGenics.
NCT02193945 is a clinical trial that has completed, run by ThromboGenics. The registered enrollment target is 134 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02193945 has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- 134 participants
- Enrollment target
Study Summary
The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (VMA) with JETREA® (ocriplasmin), including incidence, time to onset and resolution of anatomy and symptoms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-05 |
What the finished NCT02193945 record still lists
NCT02193945 is an observational study that tracks outcomes without assigning an intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02193945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02193945 about?
NCT02193945 is a clinical study titled "A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA". The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (VMA) with JETREA® (ocriplasmin), including incidence, time to onset and resolution of anatomy and sy...
What is the current status of trial NCT02193945?
This trial is currently completed. The enrollment target is 134 participants. The study started on 2014-08. Estimated completion is 2015-05.
Who is sponsoring clinical trial NCT02193945?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia